Gamida Cell (GMDA) Gets a Buy Rating from Needham

Needham analyst Chad Messer assigned a Buy rating to Gamida Cell (GMDAResearch Report) today and set a price target of $14.00. The company’s shares closed last Tuesday at $6.83.

According to, Messer is a 4-star analyst with an average return of 5.1% and a 41.9% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gamida Cell with a $19.00 average price target, implying a 192.3% upside from current levels. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $19.00 price target.

See today’s analyst top recommended stocks >>

Based on Gamida Cell’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $32.3 million. In comparison, last year the company had a GAAP net loss of $14.71 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gamida Cell Ltd. is a clinical stage biopharmaceutical company engaging in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.